Newsroom

January 05, 2021- Patient enrollment began in November for this rigorous prospective, randomized, controlled PRIME intervention trial to demonstrate the value of implementing the PreTRM® prevention strategy to improve neonatal outcomes and lower cost of care.

September 9, 2020- Sera will be presenting at the upcoming Baird 2020 Global Health Care Conference. A virtual conference, Sera’s presentation will take place on Thursday, September 10 at 10:50 a.m. ET.

June 24, 2020 – Sera announced the appointment Thomas J. Garite, M.D. as Vice President of Clinical Sciences. – Dr. Garite will support clinical development and operations as Sera transitions from clinical to commercial-stage company.

May 20, 2020 – Sera, Inc., The Pregnancy Company® announced the publication of positive data in a large, independent, contemporary prospective U.S. clinical cohort study, TREETOP (NCT02787213), in the American Journal of Obstetrics & Gynecology Maternal Fetal Medicine.

April 2, 2020 – Sera announced the appointment of Jay M. Moyes as Chief Financial Officer.

Feb 24, 2020 — Sera will be presenting at the upcoming Cowen 2020 Health Care Conference at the Boston Marriott Copley Place in Boston on Tuesday, March 3rd, at 11:30 a.m. ET.

Jan 28, 2020 — Sera announced two podium presentations describing the performance of the company’s technologies for predicting the individual risk of prematurity for women when prospectively tested in mid pregnancy.

Jan 9, 2020 – Sera announced the completion of the Prevent PTB clinical study conducted by Intermountain Healthcare. This study is the first of its kind to measure the impact on maternal and neonatal health and healthcare costs when standard medical interventions are used to proactively treat mothers screened at high risk for prematurity by the PreTRM® Test.

Jan 6, 2020 — Sera will be presenting at the upcoming JP Morgan 2020 Healthcare Conference at the Westin St. Francis Hotel in San Francisco on Wednesday, January 15th, at 3:30 p.m. PT.

Nov 18, 2019 – Sera announced that a key scientific publication, “Effects of Selective Exclusion of Patients on Preterm Birth Test Performance,” authenticates Sera as the leading authority in using biomarkers to assess preterm birth risk.